There may be instances where patients are unable to purchase oral cyanocobalamin such as those with reduced mobility, in care homes and those visiting homes restricted by Covid outbreaks / family infection
Online Trading Protection Payment Guarantee Platform-protected payments with refund support for eligible order issues
Neurological: convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment, vertigo, headache Endocrine: menstrual irregularities, development of cushingoid state, suppression of fetal intrauterine or childhood growth, lack of secondary response of the adrenal cortex or pituitary gland, particularly in situations of stress such as trauma, surgery or illness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetic patients Ophtalmic: posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos Metabolic: negative nitrogen balance due to protein catabolism Psychiatric: euphoria, mood swings, severe depression to frank psychotic manifestations, personality changes, hyperirritability, insomnia Others: anaphylactoid or hypertensive reactions and hypotension or shock-like reaction Cyanocobalamin and hydroxocobalamin: hypervitaminosis and side effects were not observed with their use Dosage and administration Adults Coated tablets: 1 coated tablet 2 times a day
Verify the current MUE table for CPT 96372 against the April 2026 release before billing multiple units on the same date of service Source: CMS MUE Table GLP-1 Coverage Expansion: Medicare Part B coverage for GLP-1 agents used for obesity management is expanding in 2026
Folate and cobalamin deficiency in megaloblastic anemia in children
